Working… Menu

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03425279
Recruitment Status : Recruiting
First Posted : February 7, 2018
Last Update Posted : June 16, 2020
Information provided by (Responsible Party):
BioAtla, Inc.

Brief Summary:
The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in solid tumors

Condition or disease Intervention/treatment Phase
Solid Tumor Non Small Cell Lung Cancer Pancreatic Cancer Melanoma Sarcoma Sarcoma, Ewing Osteosarcoma Leiomyosarcoma Synovial Sarcoma Liposarcoma Soft Tissue Sarcoma Bone Sarcoma Refractory Sarcoma Biological: CAB-AXL-ADC Phase 1 Phase 2

Detailed Description:

This is a multi-center, open-label, Phase 1/2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC) in patients with advanced solid tumors in Phase 1 and BA3011 alone and in combination with nivolumab in Phase 2.

Phase 1 of this study will consist of a dose escalation phase (enrollment complete as of Oct 2019) and a dose expansion phase (still enrolling).

Phase 2 is targeted to begin in Q3 2020 and will include both adult and adolescents age 12 and over.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
Actual Study Start Date : February 15, 2018
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : January 2022

Arm Intervention/treatment
Experimental: BA3011
Phase 1: All patients will receive BA3011, CAB-AXL-ADC. Phase 2: All patients will receive either BA3011 alone or in combination with nivolumab.
Biological: CAB-AXL-ADC
Conditionally active biologic anti-AXL antibody drug conjugate

Primary Outcome Measures :
  1. Frequency and severity of Treatment-Emergent Adverse Events (Safety and Tolerability of BA3011) [ Time Frame: Up to 24 months ]
    Measured by frequency and severity of adverse events

  2. Dose Limiting Toxicities (DLTs) [ Time Frame: DLT will be assessed from first treatment cycle (3 weeks) ]
    Number of DLTs

  3. Maximum Tolerated Dose (MTD) [ Time Frame: [Time Frame: MTD will be assessed from first treatment cycle (3 weeks)] ]
    Number of DLTs

  4. Anti-tumor activity [ Time Frame: Up to 24 months ]
    Overall Response Rate (ORR) according to RECIST version 1.1

Secondary Outcome Measures :
  1. Pharmacokinetics: Cmax [ Time Frame: Up to 24 months ]
    Maximum observed concentration of BA3011

  2. Pharmacokinetics: AUC [ Time Frame: Up to 24 months ]
    Area under the concentration versus time curve of BA3011

  3. Immunogenicity of BA3011 [ Time Frame: Up to 24 months ]
    Presence of anti-drug antibodies (ADA)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have measurable disease.
  • Age ≥ 18 years (Phase 1); Age ≥ 12 years (Phase 2)
  • Adequate renal function
  • Adequate liver function
  • Adequate hematological function
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy of at least three months.

Exclusion Criteria:

  • Patients must not have clinically significant cardiac disease.
  • Patients must not have known non-controlled CNS metastasis.
  • Patients must not have received granulocyte colony stimulating factor (G-CSF) or granulocyte/macrophage colony stimulating factor support 3 weeks prior to first BA3011 administration. (Phase 1 only)
  • Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.
  • Patients must not have Grade 2 or higher peripheral neuropathy.
  • Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
  • Patients must not be women who are pregnant or breast feeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03425279

Layout table for location contacts
Contact: Hazel Buncab, AD, ClinOps 858-263-1598 ext 8582631598
Contact: Gerlee Thomas, Head of Regulatory 858-263-1598

Layout table for location information
United States, Colorado
University of Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Tate Closson-Niese    720-848-0669   
Contact: Emily Drees    720-848-0719    EMILY.DREES@CUANSCHUTZ.EDU   
Principal Investigator: Robert Doebele, MD         
Sarah Cannon Research Institute at Health One Recruiting
Denver, Colorado, United States, 80218
Contact: Maddie Goral, MD    720-754-2659   
Principal Investigator: Shiraj Sen, MD         
United States, Florida
Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 33612
Contact: Milijana Ugrenovic-Petrovic   
Contact: Soha Riad   
Principal Investigator: Mihaela Druta, MD         
United States, Nevada
Comprehensive Cancer Center of Nevada Recruiting
Las Vegas, Nevada, United States, 89169
Contact: Johanna Schmit, MD    702-952-3724   
Principal Investigator: Fadi Braiteh, MD         
United States, New York
Columbia University Recruiting
New York, New York, United States, 10032
Contact: Olivia Mead    212-304-5292   
Principal Investigator: Matthew Ingham, MD         
Memorial Sloan Kettering Recruiting
New York, New York, United States, 10065
Contact: Kelsey Ricci    646-888-4303   
Principal Investigator: Eileen M. O'Reilly, MD         
United States, Oregon
Oregon Health & Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Zach Godwin    503-418-9324   
Principal Investigator: Jacqueline Vuky, MD         
United States, Tennessee
Tennessee Oncology Recruiting
Nashville, Tennessee, United States, 37203
Contact: Howard Burris, MD   
Principal Investigator: Howard Burris, MD         
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Jordi Rodon    713-792-8927   
Contact: Diep T Tran    713-792-8927   
Principal Investigator: Jordi Rodon, MD         
Sponsors and Collaborators
BioAtla, Inc.
Layout table for additonal information
Responsible Party: BioAtla, Inc. Identifier: NCT03425279    
Other Study ID Numbers: BA3011-001
First Posted: February 7, 2018    Key Record Dates
Last Update Posted: June 16, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by BioAtla, Inc.:
late stage
stage 3
stage 4
Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoma, Synovial
Sarcoma, Ewing
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Muscle Tissue
Neoplasms, Adipose Tissue
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neoplasms, Glandular and Epithelial